ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO171

Effect of Hypomagnesemia on Vascular Calcification in Peritoneal Dialysis Patients

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical

Authors

  • Kang, Minjung, Seoul National University Hospital, Seoul, Korea (the Republic of)
  • Kang, Eunjeong, Seoul National University Hospital, Seoul, Korea (the Republic of)
  • Ryu, Hyunjin, Seoul National University Hospital, Seoul, Korea (the Republic of)
  • Ahn, Curie, Seoul National University Hospital, Seoul, Korea (the Republic of)
  • Oh, Kook-Hwan, Seoul National University Hospital, Seoul, Korea (the Republic of)
Background

Vascular calcification is a non-traditional risk factor for cardiovascular disease in patients with chronic kidney disease (CKD) and main cause of this is disturbance in the mineral and bone metabolism. Magnesium (Mg) was known as a calcification inhibitor and there was a high prevalence of hypomagnesemia in peritoneal dialysis (PD) patients. However, a longitudinal study of the effects of hypomagnesemia on vascular calcification in PD patients was rare.

Methods

167 patients with PD were included from Seoul National University Hospital. We investigated the relationship between lower serum magnesium and vascular calcification progression. Patients were categorized as hypomagnesemia (n=20), normomagnesemia (n=85), and hypermagnesemia (n=62). Vascular calcification was assessed by abdominal aortic calcification (AAC) score with lateral lumbosacral X-ray. The study end point was vascular calcification progression, defined as the change in AAC score per year >0.

Results

During the median follow-up period of 3.1 years [interquartile range 2.0-4.3 years; maximum 7.6 years], 38 (42.7%) patients developed vascular calcification progression. In a multivariable logistic regression model, the hypomagnesemia group was associated with higher risk of vascular calcification progression (C1, serum Mg ≤ 1.7 mg/dl, OR 27.3 [1.07 – 691.2]; P=0.045), as compared with the normal range magnesium group. All-cause mortality was not associated with hypomagnesemia in a multivariable hazard model (C1, serum Mg ≤ 1.7 mg/dl, HR 0.7 [0.07 – 6.89]; P=0.755).

Conclusion

Hypomagnesemia is associated with vascular calcification progression in peritoneal dialysis patients.